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Despite being the population group that receive the largest number
of drug prescriptions annually, older patients are generally not included
in Phase 1 clinical trials during drug development. Complex pathophys-
iology, variability in organ function and the presence of co-medication
are some of the factors that may account for the exclusion of older
patients from clinical pharmacokinetic (PK) studies. Drug dose regi-
mens used in the older patients are frequently determined by trial and
error or extrapolated from doses relevant to young adults. Such extrap-
olations may not be appropriate since the scaling factors like age and
weight that are used for extrapolation may not be linearly related to
the PK variability associated with the older patient [1]. Considerable
variability in drug response exists in the older patient [2,3], making
dose selection very complex. In the absence of well-designed and
appropriate clinical trials focused on the older patient, modelling and
simulation offers a good tool to understand PK and pharmacodynamic
(PD) variability and their impact on drug doses in this population.
Systems biology endeavours to quantify the contributions of themo-
lecular elements of a biological system to assess their interactions and to
integrate that information into models that can provide predictive hy-
potheses to explain the behaviours of the biological system when sub-
jected to changes and different environmental exposures [4]. Systems
pharmacology, a science pertinent to the study of drugs, has been de-
scribed as a marriage between physiologically based pharmacokinetic
(PBPK) modelling and in vitro-in vivo extrapolation (IVIVE) techniquesFig. 1. Schematic representation of the systems pharmacology approaunder the umbrella of systems biology [5]. PBPK models encompass
the principles of systems biology and constitute a modelling approach
that describes the absorption and disposition of drug molecules as
well as their biological and physiological drivers. An increased under-
standing of these physiological and biological drivers and their interac-
tions with different drug molecules and formulations provide valuable
insights into how drugs will behave in healthy volunteers and other
population groups such as patients with diseases or extremes of age
[6]. As illustrated in Fig. 1, based on the systems pharmacology
approach, PBPK models constitute three essential components. These
include biological and physiological factors relevant to the human
body (systems related properties such as age, weight, sex, genetics,
organ size and blood ﬂow, enzyme abundance and activity, ethnicity
etc.), drug related properties (e.g. physiochemical properties that deter-
mine permeability throughmembranes, protein binding, binding to en-
zymes and transporters etc.) and the study trial design (dose, frequency
of dosing, duration of the study etc.). These components are combined
and integrated mechanistically, enabling the simulation and prediction
of PK/PD parameters and concentration-time and response-time pro-
ﬁles in virtual populations. Considering the progressive biological and
physiological changes that accompany the process of aging, together
with co-existing diseases and polypharmacy, IVIVE-linked PBPKmodels
are ideally suited to predict the impact of these variables on the absorp-
tion and disposition of drugs in older patients. While PBPK modelling
has the potential for mapping inter-individual variability in drug con-
centrations that reach the plasma following delivery by differentch to population pharmacokinetic/pharmacodynamic modelling.
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concentrations in the different organs in the body, whichmay be related
to the site of action of the drug. A further advantage of using PBPK
models is that ‘what if’ scenarios can be simulated to obtain information
on the ‘worst case’ scenarios that cannot normally be tested in a clinical
trial but may emerge after the drug is marketed.
Depending on the application, the structure of the PBPK model
may be simple (minimal PBPK model) such as that shown in Fig. 2A
(where all the tissues besides the liver and gut are lumped together
as a single compartment) or more complex (whole body PBPK
model), where all the major tissue compartments in the body are rep-
resented (Fig. 2B). Drug movement between the different tissues/or-
gans are simulated using differential equations. Each organ
compartment can be a simple static compartment with passive per-
meability or more mechanistic, where variables such as transporters,
metabolizing enzymes and differential drug permeability are consid-
ered. Detailed descriptions of PBPK models, data requirements for ef-
fective PBPK models, differential equations used and applications in
drug development and regulatory submissions have been extensively
reviewed [5–12]. In this paper, applications of PBPK models to evalu-
ate drug absorption, distribution, metabolism and excretion (ADME)
in older subjects, following administration parenterally, orally and
topically are presented. We also brieﬂy discuss the role of
formulation-related issues regarding variability and how they may in-
terplay with age. The latter may be considered as re-visiting the
wisdom of conducting bioequivalence studies in healthy volunteers
rather than the patient groups for whom the drug product is intended,
especially for drugs with properties such as pH dependent release and
dissolution.2. Overview of the methods used to predict PK parameters using
IVIVE-linked PBPKmodels
This overview describes the PBPK models available in the Simcyp
population based simulator. The brief summary should serve to illus-
trate how changes in the systems parameters can impact quantitatively
on the PK of the drug.Fig. 2. A.Minimal physiologically-based pharmacokinetic model with (lower) single adjusting c
respectively; kin and kout are ﬁrst order rate constants which act on themasses of drugwithin th
clearance (Q) can be used; IV and PO are intravenous and oral dosing routes respectively
pharmacokinetic model. QH, QHA, QPV, QG, QT,A and QT are blood ﬂows in the hepatic vein, h
(T) compartments, respectively; EG and EH are the fractions undergoing ﬁrst pass metabolism
absorbed and the ﬁrst order absorption rate constant, respectively.2.1. Study Population
Default Simcyp parameter values required for creating a virtual
North European Caucasian population (e.g. physiological parameters in-
cluding liver volume and blood ﬂows, enzyme abundances etc.) have
been described previously [13]. Demographics, physiological and ana-
tomical parameter values obtained from extensive literature searches
are used to generate each study population, with variability between
the subjects in the population. While the North European Caucasian
population is the base population within the simulator, parameter
changes relevant to other populations, such as Chinese or geriatrics,
can be used to generate the special populations.
2.2. Prediction of PK
2.2.1. Absorption
Drug delivery from various routes of administration and different
dosage forms can beused in theprediction of absorption anddisposition
of drugs. Oral absorption will be discussed brieﬂy here since this is the
most common route for drug delivery. Predictions can be made using
a ﬁrst-order absorption model, a compartmental absorption transit
(CAT) model [14] or the advanced dissolution absorption metabolism
(ADAM) model [11].
Bioavailability (F) of orally administered solid dosage forms involves
release of the drug from the formulation, dissolution in the biological
ﬂuids, passage through the gut wall, and passage through the liver be-
fore it reaches the systemic circulation. Consequently, the following
three parameters need to be considered: the fraction of the dose that
enters the gut wall (fa), the fraction that escapes metabolism in the
gut wall and enters the portal vein (FG), and the fraction that enters
the liver and escapes metabolism (FH). The total bioavailability is the
product of these three components (i.e., F = fa × FG × FH).
When the ﬁrst-order absorption model is used, clinically observed
inputs for the ﬁrst order absorption rate constant (ka) and fraction
absorbed (fa) can be used. Alternatively, these parameters can be pre-
dicted from an estimate of in vivo permeability, Peff,man, and the radius
of the small intestine (R) [14], using Eqs. (1) and (2) below:
ka ¼ 2 Peff ;man
R
ð1Þompartment. QH, QPV, and QHA are blood ﬂows in the liver, portal vein, and hepatic artery,
e systemic compartment and the SAC respectively, alternatively, the inter-compartmental
; ka is the ﬁrst order absorption rate constant. B. Whole body physiologically-based
epatic artery, hepatic portal vein, gut and blood ﬂows into and out of the other tissue
in the gut and liver, respectively; CLR is the renal clearance; fa and ka are the fraction
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 −7 ð2Þ
The fraction of drug that escapes ﬁrst pass metabolism and enters
the portal vein (FG) is inﬂuenced by the presence of enzymes and trans-
porters in the gut [15]. FG can be estimated using Eq. (3) [16],whereQgut
is a blood ﬂow parameter, fugut is the unbound drug fraction in the gut
and CLuG,int represents the gut intrinsic clearance:
FG ¼
Qgut
Qgut þ fugut  CLuG; int
ð3Þ
The fraction avoiding ﬁrst-pass metabolism in the liver (FH), can be
calculated using Eq. (4), whereQH (hepatic bloodﬂow), fuB (the fraction
of drug unbound in blood) and Cluint,H (intrinsic metabolic clearance)
are the primary determinants of net hepatic clearance (CLH):
FH ¼ QHQH þ fuB:CLu int ;H
ð4Þ
Fig. 3A illustrates a typical PBPK model for absorption that accounts
for the differences in enzyme abundance (e.g. CYP3A4) and transporter
abundance (e.g. P-glycoprotein) along the gastrointestinal tract. The
model also accounts for other differences such as pH along the different
segments. Fig. 3B represents a section of the small intestine, illustrating
all the processes that can be simulated using ADAM [17].
2.2.2. Distribution
Factors such as tissue volumes and plasma:tissue partition
coefﬁcients are considered when predicting the volume of distribution
of a drug. The following equation is used to predict Vss when using the
minimal PBPK model:
Vss ¼
X
Vt  Pt:p
 
þ Ve  E : Pð Þ þ Vp ð5Þ
Where V is the fractional body volume (L/kg) of a tissue (t), erythro-
cyte (e), or plasma (p), E:P is the erythrocyte:plasma ratio and Pt:p is the
partition coefﬁcient for non-adipose and adipose components [18].
2.2.3. Elimination
Metabolic drug elimination is deﬁned inmany physiologically based
models using input data on intrinsic clearance (CLint). This is scaled up
based on speciﬁc enzyme abundance (CYP in case below), a scaling fac-
tor depending on which system is used (e.g. microsomes (MPPGL),Fig. 3. A. Structure of the ADAMmodel in which the GI tract is divided into 9 sections with segr
each segment varies non-monotonically along the intestine as indicated by the varying intensity
[17]. B. Segment of the small intestine indicating the various processes that can be simulated.hepatocytes etc.) and organ size (usually liver but could be kidney) to
give an intrinsic clearance for the whole organ (Eq. (6)).
CLint ¼
Xn
j¼1
CL int j  CYPjabundance
 
2
4
3
5MPPGL  Liver Weight ð6Þ
Thewhole organ intrinsic clearance is then scaled upusing a suitable
model, usually the ‘well stirred model’ incorporating data on fraction of
drug unbound in blood (fuB), the whole organ intrinsic clearance (CLint)
values from all enzyme pathways and organ blood ﬂow (QH) (Eq. (7)).
The overall metabolic clearance in each organ is then added to the
renal, biliary and any additional systemic clearance values to give the
overall elimination of the drug.
CLH ¼ QH  fuB  CLuintQH þ fuB  CLuintð Þ
ð7Þ
3. PBPK modelling in geriatric populations
PBPK models covering the geriatric population have been published
previously [19,20], andwere reported to predict PK parameters for a va-
riety of drugs used in the elderly with reasonable accuracy. Many of the
systems parameters, which form an important part of these models,
change with age. A brief summary of the main changes likely to give
rise to altered drug disposition in the older population is given below.
These are included as part of the Simcyp PBPK Geriatric population
and it is the development of this model that we concentrate on below.
The database of Thompson et al. can be used as a starting point for estab-
lishing PBPK for the geriatric populationwhich included thoseN65 years
[21]. The review below mainly focusses on the major determinants of
the factors governing drug elimination with mention of other areas rel-
evant to building PBPKmodels in the geriatric population. For all param-
eters, only the changes resulting from the normal aging process are
included. Whilst it is acknowledged that older patients often develop
disease, those with overt renal or hepatic impairment are included in
separate PBPK populations (moderate/severe renal impairment or
liver cirrhosis Child-Pugh A, B, C) discussed previously [22,23].
3.1. Demographics
The typical age distribution seen in the elderly population is shown
in Fig. 4A. This can be incorporated into PBPK using a Weibull function.egated blood ﬂows to each section. The abundance of various enzymes and transporters in
of the colour for each section (CYP3Adistribution is indicated in purple and P-gp in green).
[17].
Fig. 4. A. The age distribution of a North European Geriatric population. Black and grey bars are males and females, respectively.B. The height vs age relationship for males, the black sym-
bols are individual patient data from Health Survey for England data 2009 and the grey lines are best ﬁt regression lines utilized in the geriatric PBPK model. C. The weight vs height re-
lationship for males, the black symbols are individual patient data from Health Survey for England data 2009 and the grey lines are best ﬁt regression lines utilized in the geriatric PBPK
model.
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height increased in older age bands [20]. This is shown Fig. 4B based on
Health survey for the UK [24]. To ensure a correlated Monte-Carlo ap-
proach body weight should be modelled based on height (Fig. 4C).
This prevents the simulation of physiologically implausible virtual sub-
jects. Similar to height, body weight also tends to decline in the older
population with more rapid decline in older age bands.
3.2. Absorption
For oral absorption there is conﬂicting evidence on changes in gas-
tric emptying (GE) and intestinal transit times (ITT) in the elderly,
with studies showing both longer and shorter GE and ITT in this age
group compared to a young adult group. Consequently, this parameter
was left unchanged in the geriatric PBPK population [25,26]. There is ev-
idence of a 10% increase in the Inter digestiveMigratingMotor Complex
in subjects in their eight decade compared to young adults. Weighted
average was 112.4 min in 82 year olds (n= 25) compared to 102 min
in 31 year olds (n=29) [27,28]. This could impact on the biliary excre-
tion of drugs and subsequently enterohepatic recirculation in the
elderly.
3.3. Distribution
There are many organ systems where there is a decline in organ size
with age and this has been reviewed in detail by Schlender et al. 2016
[20]. Within a PBPK model, changes to organ blood ﬂows are related
to the decline in cardiac output with age [29–31]. This is shown forcardiac output in males in Fig. 5A with simulated data compared to ob-
served data.
3.4. Drug elimination
The main changes to the processes that may alter drug elimination
with age and that will need to be incorporated into any geriatric PBPK
model are given in the individual sections below.
3.4.1. Metabolism
Various studies have investigated age related changes in CYP en-
zymes with some conﬂicting results. Blanco et al. [32] investigated age
related changes in microsomal CYP1A2 (ethoxyresoruﬁn), CYP2E1
(ethoxycoumarin), CYP3A4/5 (midazolam) and CYP2C8 (paclitaxel
17α position) and found no age related change in activity between sub-
jects N60 years compared to those N10 to 59 years. PreviouslyHunt et al.
had also demonstrated no change in CYP3A activity in vitro with age
(range 27 to 83 years) [33] and also in vivo using the erythromycin
breath test between an older (70 to 88 years) compared to a younger
age group (20 to 60 years) [34]. In another study the same authors
showed no change in CYP2E1 activity over the range of 30 to 75 years
[35]. Schmucker et al also demonstrated the absence of signiﬁcant age
differences in the activities and content of human liver
monooxygenases [36]. In contrast George et al had shown a negative as-
sociation between expression of CYP2E1 and CYP3A and older age [37].
A study by Parkinson et al 2004 investigated the effects of age on CYP
activity in human liver microsomes [38]. Data was arranged into three
age groups b20 y, 20 to 60 y and N60 y, each age group was composed
of a minimum of 19 samples. Only CYPs 1A2, 2D6 and 2E1 were found
Fig. 5. Example ‘Systems’ data against age used in the geriatric PBPKmodel showing values generated by themodel againstmeasured values from the literature. Cardiac output formales is
shown inA, liver weight for females is shown inB, liver blood ﬂow for bothmales and females in C and GFR for males is shown inD. Grey symbols aremodel generated values and various
black symbols are measured values (see references).
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regression analysis, however, CYPs 1A2, 2B6, 2C19, 2D6 and 2E1 ap-
peared to decrease N25% whilst CYPs 2A6 and 4A11 appeared to in-
crease N25% between the oldest and youngest groups.
A study of in vivo drug metabolism based around administration of
probe drug substrates to children and adolescents b19 years, adults 20
to 64 years and elderly adults N64 years [39] showed a decrease in me-
tabolism of CYP1A2 (caffeine, theophylline), CYP2C9 tolbutamide, phe-
nytoin and ibuprofen), CYP2C19 (amitriptyline and nortriptyline),
CYP2E1 (acetaminophen) and CYP3A4 (midazolam, lidocaine and
terfenadine) with increasing age. Whilst the suitability of a number of
these probe drugs is questionable, a clear trend was observed but in
light of other results these observations may have more to do with re-
ducing liver size and blood ﬂow rather than changes in speciﬁc enzyme
expression and activity. In theﬁnal PBPKmodel no changeswere imple-
mented to the expression of CYP enzymes in the geriatric population
and the same values as per the North European Caucasian population
were used.
Older age is thought to have only a modest, if any, effect on hepatic
glucuronidation of certain drugs in vivo [40], this is in agreement with
in vitro data from a number of studies. Herd et al. [41] studied paraceta-
mol glucuronidation (later conﬁrmed as UGTs1A1, 1A9 and 2B15 [42])
activity in microsomes prepared from livers from individuals aged 44
to 89 years, and there was no signiﬁcant correlationwith age. Parkinson
et al. [36] measured UGT activity in hepatocytes prepared from those
aged 20 to 60 and those aged N60 years using 4-methylumbelliferone
as a probe and found no difference between the groups. Further to
this, Court et al. [43] studied age related changes in UGT activity in
liver microsomes prepared from 55 individuals aged 5 to 75 years, tak-
ing out the paediatric liver samples this left data from 47 individuals
N20 years and of these 13 who were N60 years. Using probe substrates,
estradiol (UGT1A1), triﬂuoperazine (UGT1A4), serotonin (UGT1A6),propofol (UGT1A9), zidovudine (UGT2B7) and oxazepam (UGT2B15),
again no age related changes in activity were observed between donors
N60 and those b60 years. There is no evidence that the expression of
UGT enzymes should be altered for the geriatric population in a PBPK
model.
Little data exists for effects of older age on other drug metabolizing
enzymes, the study by Herd et al. [41] additionally measured paraceta-
mol sulphation from the cytosolic fractions in subjects 40 to 89 years
and, similar to glucuronidation, found no correlation with age. A study
by Farah et al. [44] measured the rate of acetylation of isoniazid in
young adults (20 to 35 years) vs. the elderly (N65 years) and found no
difference between the two populations. Finally Woodhouse et al. [45]
measured both hepatic glutathione concentration and epoxide hydro-
lase activity and found no change with age.
3.4.2. Liver size
There is good evidence that liver size decreases with increasing age
in the adult population with the decrease becoming more pronounced
after 60 years of age [46–51], this data is summarized for females in
Fig. 5B. The reduced effective liver mass results in a reduced capacity
for drug elimination (Eq. (6)). This is matched by biopsy data showing
a reduced number of hepatocytes in livers from elderly subjects [34].
The reduced liver size is incorporated into the geriatric population
PBPK model.
3.4.3. Liver blood ﬂow
The liver blood ﬂow is deﬁned in the geriatric PBPKmodel as a ﬁxed
percentage of cardiac output and hence is reduced with age, this is in
agreement with observed data [52,53]. The simulated liver blood ﬂow
for males and females with some measured data are shown in Fig. 5C.
In a study by Wynne et al. there was a signiﬁcant negative correlation
between indocyamine green clearance and apparent liver blood ﬂow
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clearance for particularly intermediate and high extraction drugs in
the elderly. Castleden et al. [54] showed a reduced systemic clearance
of propranolol in older subject (mean age 78 years) compared to a
younger group (mean age 29 years), they also showed higher bioavail-
ability in the elderly due to reduced ﬁrst-pass metabolism.3.4.4. Protein binding
There appear to be very little change in plasma albumin concentra-
tions with older age based on observed data [55–57] this is in agree-
ment with the algorithms already used in the geriatric PBPK model
which calculates albumin based on BMI and age. The observed data for
older age related changes in alpha-1-acid glycoprotein show either no
change [57] or a slight reduction with older age [56], no change with
age for α-1 acid glycoprotein is currently included in the geriatric pop-
ulation PBPK model.3.4.5. Renal elimination
The age related decline in renal function is well known [58–61]. The
age related changes in glomerular ﬁltration rate (GFR) in geriatric PBPK
model are calculated using age related plasma creatinine data derived
from the NHANES database [62] using either the Cockcroft-Gault or
modiﬁed diet in Renal disease equations. The simulated and observed
changes in GFR in older age are shown in Fig. 5D.
The magnitude of the changes in system parameters in the geriatric
compared to HVpopulationswithin a PBPKmodel are shown in Table 1.
The effects of these changes on the degree of change in the PK of actual
and theoretical drugs of different extraction ratio has been predicted by
the model and the results are in line with what is expected.Table 1
Summary of changes to system parameters within a geriatric PBPK model resulting in altered
ADME System
parameter
Change
compared to
healthy
volunteer
population
(Literature)
Changes to system
parameters;
geriatric PBPK model
(65 to 95y)
compared to Healthy
volunteer (20
to 50 y)
Changes
paramet
age in
geriatric
model (6
compare
Absorption Gastric emptying ↑↓ None –
Intestinal transit time ↑↓ None –
Inter-digestive motor
complex
↔↑ None –
Distribution Organ size ↓ ↓ (see below for liver) –
Cardiac output (organ
blood ﬂows)
↓ ~18% ↓e ~16% ↓
Albumin ↔ ~2% ↓f ~3% ↓
α1-acid glycoprotein ↓↔ None –
Metabolism Liver weight ↓ ~21% ↓g ~35% ↓
MPPGL ↔ ~28% ↓e ~3% ↓
Liver blood ﬂow See Cardiac output
CYP ↔ ↓ None
UGT ↔ ↓ None
Elimination Renal via GFR ↓ ~47% ↓h ~45% ↓
a Intermediate extraction drug.
b Low extraction drug.
c High extraction drug.
d Renally cleared drug.
e Changes described in PBPK model using an age related equation in PBPK model.
f Changes described in PBPK model using an age and BSA related equation in PBPK model.
g Changes described in PBPK model using a BSA related equation up to 65y then an addition
h Changes described in PBPK model via age related changes in serum creatinine.3.5. Prediction of clearance and exposure to six drugs in virtual geriatric pa-
tients following oral or parenteral administration
Clinical data on the PK of caffeine [64], desipramine [65], midazolam
[66], digoxin [67], warfarin [19], triazolam [68] and omeprazole [69] in
older patients was extracted from the literature. These compounds
were available in the Simcyp compound library and literature data com-
paring the PK in younger and older subjects were available for compar-
ison with predicted data. Initially, availability of clinical data that
compares PK in young and older subjects is essential for performance
veriﬁcation of the PBPK models. The Geriatrics model described above
was used to simulate the published studies and the predicted clearance
and AUC was compared with the clinically observed values. Fig. 6A
shows the predicted clearance values relative to the observed clearance
and it can be seen that there is acceptable recovery of the observed data
by the model. Fig. 6B shows the ratio of the predicted and observed %
decrease in clearance between young and elderly patients. All these ra-
tios are ≤1.5 (Fig. 6B) suggesting good recovery of the comparative clin-
ical data between young and elderly subjects. While plasma
concentrations in the older subjects were generally higher, some drug
concentrations, such as those for midazolam, suggest that lower dos-
ages may be more appropriate in this patient group.
Schlender and co-workers [20] used parenterally administeredmor-
phine and furosemide to verify a geriatrics model that they had devel-
oped. Satisfactory recovery of the clinical data was reported. These
results indicate that both the Geriatrics models were successful in the
prediction of exposure of these drugs following oral and parenteral de-
livery. Following veriﬁcation of PBPKmodels, they can be used prospec-
tively to predict differences in drug exposure between young and
elderly subjects from different dosage formulations. Such predictions
can assist with dosage adjustments in the elderly.ADME and thus predicted PK compared to a healthy volunteer population.
to system
ers with
PBPK
5
d to 95 y)
Likely signiﬁcance on predicted PK
in elderly via PBPK model
References
V low [25,26]
V low [25,26]
V low [27,28]
V low (except liver) [20]
Low to Moderate (see liver blood ﬂow) [52,53]
None [55–57]
None [56,57]
Moderate to high e.g. Midazolama CL ↓32%,
Midazolam with 10% CLintb then CL ↓40%
in geriatrics vs HV
[46–51]
[63]
Moderate for high extraction drugs e.g.
Dextromethorphanc CL ↓22% in geriatric vs HV
Low/Moderate See text
Low/Moderate See text
Moderate to high e.g. Vancomycind CL ↓47% in geriatric vs
HV
[58–62]
al age related equation.
Fig. 6. A. Predicted clearance values relative to the observed clearance in geriatric patients. B. Ratios of the predicted and observed % decrease in clearance between young and elderly
patients.
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PBPKmodels are also useful tools allowing for prediction of systemic
exposure following dermal administration. Combining information on
genetic, physiological and demographic variability with preclinical
in vitrodata to allow extrapolation to in vivopopulation pharmacokinet-
ics, the development of databases andmodels for dermal absorption can
be considered as major advancement in the area of pharmaceutical sci-
ence and drug delivery. A mechanistic dermal absorption model in-
formed by human physiology (e.g. skin layer thickness, lipid contents,
blood ﬂow rates, etc.) was developed and integrated into the Simcyp
Simulator to predict human dermal absorption of drugs [70]. ThisFig. 7. Structure of the MechDermA mechanistic multi layer dermal absorption model shmodel was validated using 5 different diclofenac formulations. The ef-
fect of penetration enhancers, site of application, gender and ethnic var-
iations were also incorporated in the simulated clinical trials. Good
recovery of the observed drug exposure and population variability
was evident in all ﬁve validation studies.
An enhanced version of this model is a transient, multi-phase
and multi-layer (MPML) mechanistic dermal absorption model
(MechDermA). The MPML MechDermA model (as shown in Fig. 7) is
divided into several components: (1) formulation, (2) separate layers
- stratum corneum, viable epidermis, dermis, subcutaneous tissue,mus-
cle, (3) hair follicle, and (4) local vasculature (blood circulation). The
model accounts for longitudinal diffusion and distribution processesowing the variables that may impact on absorption through each layer of the skin.
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diffusion pathway, keratin adsorption kinetics, stratum corneum (SC)
hydration state, hair follicular transport, pH at the skin surface and
within the SC layers, etc.) and drug/formulation speciﬁc parameters
(i.e. ionization at the skin surface, lipophilicity, vehicle viscosity, etc.).
The model accounts for variability in dermal physiology to simulate
within-subject (multiple locations available) and between-subject var-
iability, including the sex and age effect. Additionally MPML differenti-
ates between various formulations beginning from simple solutions,
through emulsions, pastes, and patches. The input parameters include
in vitromeasured formulation-speciﬁc information (i.e. in vitro release,
number of micelles, viscosity etc.). Regardless of the formulation stud-
ied evaporation of the solvent can also be accounted for.
Age related changes to the physiology inﬂuence the ADME pro-
cesses, and this includes disposition of drugs and other xenobiotics ap-
plied topically. The most commonly measured physiological properties
of skin that inﬂuence the skin absorption are pH, skin and subcutaneous
layers thickness and composition (amount and type of proteins and
lipids as well as water content and their mutual ratios), local blood
ﬂow and the number of hair follicles. The MPML MechDermA PBPK
model can be transformed into a model for dermal absorption in the
older subjects based on parameter changes described below:4.1. Skin surface pH
A meta-analysis of the skin surface pH data shows that in the volar
forearm, neck and forehead there is a slight increase in this parameter
in the elderly. However, measurement of pH at different areas of the
back show a slight decrease in pH in elderly [71–78]. This could inﬂu-
ence the absorption rate in the elderly, based on the site of application
of the drug formulation.Table 2
Summary of changes in skin layers applicable to the MPML Geriatrics model.
Skin layer MPML geriatrics model
Stratum Corneum (SC) thickness
Corneocyte surface area Mean ratio of increase from adult to elderly
applied to model:
Cheek 1.2
Upper arm 1.3
Volar forearm 1.2
Dorsal forearm 1.7
Thigh 1.1
Forehead 1.2
Number of SC layers No change in the number of layers between
young adults and elderly included in the model
Corneocyte hydration No signiﬁcant change reported between young
adults and elderly
Thickness of the viable epidermis No signiﬁcant change between young adults and
elderly
Thickness of dermis Minor decreases in the elderly in some areas:
Upper arm 0.7
Cheek 0.9
Thickness of subcutaneous tissue Elderly
Upper arm 11 mm
Back 6.4 mm
Muscle thickness Elderly
Lower leg:
Males 16.4 mm
Females 17.4 mm
Upper leg:
Males 27.6 mm
Females 22.2 mm
Upper arm:
Males 22.7 mm
Females 16.5 mm4.2. Skin thickness
Escofﬁer and co-workers reported that skinmaintains its total thick-
ness up to about 65 years and becomes thinner thereafter [79]. How-
ever, for predicting dermal absorption of compounds it is necessary to
understand thickness of skin layers as summarized in Table 2.4.3. Blood ﬂow
Comparison of adult and elderly blood ﬂows shows no age related
differences [76,102,103].4.4. Hair follicles
Sinclair and coworkers presented a linear regression with scalp hair
follicles and age in subjects between 13 and 84 years old [104]. To our
knowledge there are no reports that compare the number of hair folli-
cles in different body sites between adults and elderly.
All the above mentioned parameters can inﬂuence the drug
dermatopharmacokinetics [105]. Roskos and colleagues presented re-
sults of the study comparing permeation of various compounds: in the
elderly comparedwith young individual [106]. According to their obser-
vations hydrophilic compounds (hydrocortisone, benzoic acid,
acetylsalicylic acid, and caffeine) absorption was signiﬁcantly lower,
whereas lipophilic drugs behaviour (testosterone and estradiol) was
not affected by age. Holdsworth et al. compared fentanyl disposition
after a 24-h application of fentanyl transdermal patch in 10 healthy el-
derly subjects 67–87 years and 6 young subjects 19–27 years [107].
The observed higher serum concentrations reﬂect increased absorption
and/or decreased clearance in the elderly.Comment References
Based on corneocyte hydration, corneocyte
dimensions and the number of dead cell layers in SC
Age-related increase in surface area of corneocytes [71,81,82]
Small studies suggested increase [77,83,84]
Large studies showed no change [79,80,85]
Capacitance was used as a measure of hydration [86,87,88]
Reported ratios indicate negligible changes [79,80,83,89,90]
Based on a meta-analysis [70,90,91]
Limited data available [92,93,94]
Age-dependent decline in thickness is faster in males [95,96,97-101]
94 M. Chetty et al. / Advanced Drug Delivery Reviews 135 (2018) 85–965. An example of interplay between age, ethnicity and formulation
leading to variable exposure
Bioequivalence studies are typically conducted in healthy volun-
teers. There has been a continuous discussion and debate on the neces-
sity of conducting bioequivalence studies in the target population of
patients (most of them being of older age). There are a variety of rea-
sons, as outlined above, which makes the kinetics of the drug different
in elderly populations. However, most of thesewould affect the drug re-
gardless of the formulation. Hence, they may not be expected to have
material impact on bioequivalence. The only exception is the impact
of formulation during the absorption phase (whether oral or non-
oral). The components of the formulation may introduce sensitivities
to age-related attributes of the gastro-intestinal tractwhich leads to dis-
parity between the drug products performance when they are com-
pared with what happens in a healthy volunteer population. We
describe such potential interplay combined with the effect of ethnic in-
ﬂuence based on a recent report.
The case involves one formulation being inﬂuenced by achlorhydria
to a much greater extent than the other. In a simulated comparison of
the test and reference nifedipine controlled release formulations, the
two formulationswere shown to be bioequivalent in healthy volunteers
(as observed in the clinical trial) but not in older Japanese subjects who
have achlorhydria. Achlorhydric patients show elevated gastric pH
which may lead to differential effects on various products of the same
drug based on pH-sensitivity of the formulation. Doki et al. [108] exam-
ined the latter via PBPK simulations involving the mechanistic oral ab-
sorption model ADAM. The virtual bioequivalence (V-BE) studies
highlighted the need for conduct of speciﬁc studies in elderly Japanese
populations where there are discrepancies in pH-sensitivity of dissolu-
tion between the test and reference formulations.
6. Conclusions
The above discussions illustrate the utility of the application of PBPK
models to predict the drug exposure resulting from different formula-
tions and different routes of administration. Prediction of the differ-
ences in systemic drug exposure between young adults and older
subjects can be used to inform clinical trial designs and highlight situa-
tionswhere dosage adjustments for the older subjects require consider-
ation. PBPKmodels are not a substitute for the conduct of clinical studies
in this population. However, they can highlight the possibility for dis-
crepant bioequivalence or drug PK from those established in healthy
volunteers and guide the conduct of clinical studies when there is ade-
quate evidence for a likely difference. This approachmay inform clinical
testing during drug development, thus avoiding the conduct of logisti-
cally more difﬁcult studies in the elderly in cases where they may not
be needed.
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